Feature | May 11, 2010| Dave Fornell

Fluid Status Monitoring May Offer Early Heart Failure Warning

Monitoring congestive heart failure patients for any worsening in their condition is based mainly on patient compliance to accurately weigh themselves every day and report any unusual symptoms. A technology introduced on Medtronic implantable electrophysiology devices may help to more closely monitor patients and alert physicians to any fluid buildup in the lungs before the patient detects any changes.

OptiVol fluid status monitoring is found on Medtronic’s latest wireless defibrillators, including the Consulta and Concerto cardiac resynchronization therapy defibrillators (CRT-Ds), and the Secura and Virtuoso implantable cardioverter-defibrillators (ICDs).

The device was tested in the Fluid Accumulation Status Trial (FAST) FDA trial from 2006 to 2008. The principal investigator was William T. Abraham, M.D., FACC, professor of internal medicine and director of the division of cardiovascular medicine at the Ohio State University Medical Center (OSU), Columbus. He said it’s a simple principle, using ICDs, pacemakers and CRTs already implanted in the body to help monitor patients. The device passes a small current through the tip of a lead to measure the resistance to the flow of electrons through the chest. As the lungs fill with water, the resistance falls. This sends an alert via Medtronic’s Carelink remote device monitoring system, or is detected with a wand during patient follow-up.

The study compared the device index to the gold standard of measuring weight. “The OptiVol performed much better than daily weight monitoring,” Dr. Abraham said. The sensitivity was 22 percent with weight measurement, compared to 76 percent with OptiVol. “We probably should not be as dependant on daily weight, but it is a standard of care because we haven’t had anything better.”

However, OptiVol is only an indicator and should not be used as a sole diagnostic tool. “It can’t be used in isolation, you can’t base your decision solely on the device data,” Dr. Abraham said. “It’s another piece of the monitoring data that goes into the clinical decision making.”

“We have a very large heart failure management program at OSU, with about 3,000 to 4,000 patients, many using the OptiVol technology,” he said.

No study has been conducted to evaluate if the feature lowers hospitalizations. However, Dr. Abraham said his experience with patients at OSU has shown a reduction in hospitalizations in some patients.

Related Content

News | Heart Failure| October 02, 2015
Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the...
AtriCure, cryoFORM cryoablation probe, launch
Technology | Ablation Systems| October 02, 2015
AtriCure Inc. launched the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety...
predicting arrhythmias, mcgill university, alternans patterns
News | EP Lab| September 28, 2015
Researchers have discovered how to predict some cardiac arrhythmias several steps before they even occur. It’s a...
ACC, atrial fibrillation registries, ablation, left atrial appendage occlusion procedures, LAAO Registry
News | Atrial Fibrillation| September 24, 2015
The American College of Cardiology (ACC) launched two new clinical registry programs in August to track real-world...
Biotronik, NORDIC ICD trial, defibrillation testing, DF testing, shock efficacy
News | Implantable Cardioverter Defibrillators (ICD)| September 24, 2015
Biotronik announced the publication of NORDIC ICD (NO Regular Defibrillation testing In Cardioverter-Defibrillator...
guideline, treating supraventricular tachycardia, ACC, AHA, HRS
News | EP Lab| September 23, 2015
A new guideline aimed at helping clinicians treat patients with supraventricular tachycardia, or a rapid heart rate,...
MedLumics, OCT, real-time assessment, catheter ablation, atrial fibrillation
Feature | EP Mapping and Imaging Systems| September 17, 2015
MedLumics has announced the completion of a successful single-case pre-clinical feasibility study of its optical...
Texas Cardiac Arrhythmia Institute, TCAI, first in United States, EpiAccess System, epicardial ablation

Image courtesy of EpiEP

News | Ablation Systems| September 15, 2015
The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first facility in the...
Medtronic, Evera, ICD, MR-conditional, MRI, FDA approval
Technology | Implantable Cardioverter Defibrillators (ICD)| September 14, 2015
Medtronic received the first U.S. Food and Drug Administration (FDA) approval for an implantable cardioverter...
Texas Heart Institute, Rice University, grant, nanotubes, heart, electrical signals
Feature | EP Lab| September 14, 2015
Texas Heart Institute (THI) announced that it has received a prestigious American Heart Association grant alongside...
Overlay Init